G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 1 045.65 INR -3.19% Market Closed
Market Cap: 128.1B INR
Have any thoughts about
Glenmark Life Sciences Ltd?
Write Note

Glenmark Life Sciences Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Life Sciences Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Other Current Assets
â‚ą15m
CAGR 3-Years
-67%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Current Assets
â‚ą20.3B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Current Assets
â‚ą10.8B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
31%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Current Assets
â‚ą23.9B
CAGR 3-Years
6%
CAGR 5-Years
-2%
CAGR 10-Years
-1%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Current Assets
â‚ą3.4B
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
1%
M
Mankind Pharma Ltd
NSE:MANKIND
Other Current Assets
â‚ą6.6B
CAGR 3-Years
68%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Life Sciences Ltd
Glance View

Market Cap
128.1B INR
Industry
Pharmaceuticals

Glenmark Life Sciences Ltd. engages in the development and manufacture of non-commoditized active pharmaceutical ingredients. The company is headquartered in Solapur, Maharashtra. The company went IPO on 2021-08-06. The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.

GLS Intrinsic Value
715.71 INR
Overvaluation 32%
Intrinsic Value
Price
G

See Also

What is Glenmark Life Sciences Ltd's Other Current Assets?
Other Current Assets
15m INR

Based on the financial report for Mar 31, 2024, Glenmark Life Sciences Ltd's Other Current Assets amounts to 15m INR.

What is Glenmark Life Sciences Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
-32%

Over the last year, the Other Current Assets growth was -94%. The average annual Other Current Assets growth rates for Glenmark Life Sciences Ltd have been -67% over the past three years , -32% over the past five years .

Back to Top